Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

[1] Doroshow DB(2021)PD-L1 as a biomarker of response to immune-checkpoint inhibitors Nat Rev Clin Oncol 18 345-362

[2] Bhalla S(2020)PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee J Thorac Oncol 15 499-519

[3] Beasley MB(2021)High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types Ann Oncol 32 661-672

[4] Sholl LM(2020)The tumor microenvironment in the response to immune checkpoint blockade therapies Front Immunol 11 784-76

[5] Kerr KM(2022)Role of the tumor immune microenvironment in tumor immunotherapy (Review) Oncol Lett 23 53-1920

[6] Gnjatic S(2021)Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy Signal Transduct Target Ther 6 72-757

[7] Lantuejoul S(2017)Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Lancet 389 67-548

[8] Sound-Tsao M(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-S346

[9] Cooper WA(2018)Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Lancet 391 748-2767

[10] Girard N(2018)TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Nature 554 544-42

[1] Doroshow DB(2021)PD-L1 as a biomarker of response to immune-checkpoint inhibitors Nat Rev Clin Oncol 18 345-362

[2] Bhalla S(2020)PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee J Thorac Oncol 15 499-519

[3] Beasley MB(2021)High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types Ann Oncol 32 661-672

[4] Sholl LM(2020)The tumor microenvironment in the response to immune checkpoint blockade therapies Front Immunol 11 784-76

[5] Kerr KM(2022)Role of the tumor immune microenvironment in tumor immunotherapy (Review) Oncol Lett 23 53-1920

[6] Gnjatic S(2021)Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy Signal Transduct Target Ther 6 72-757

[7] Lantuejoul S(2017)Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Lancet 389 67-548

[8] Sound-Tsao M(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-S346

[9] Cooper WA(2018)Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Lancet 391 748-2767

[10] Girard N(2018)TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Nature 554 544-42